HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Differential Effect of Baseline Computed Tomographic Angiography Collaterals on Clinical Outcome in Patients Enrolled in the Interventional Management of Stroke III Trial.

AbstractBACKGROUND AND PURPOSE:
In the Interventional Management of Stroke (IMS) III trial, we sought to demonstrate evidence of a differential treatment effect of endovascular treatment of acute ischemic stroke compared with intravenous tissue-type plasminogen activator, according to baseline collateral status measured using computed tomographic angiography.
METHODS:
Of 656 patients enrolled in Interventional Management of Stroke III trial, 306 had baseline computed tomographic angiography. Of these, 185 patients had M1 middle cerebral artery ± intracranial internal carotid artery occlusion, where baseline collateral status could be measured. Collateral status was assessed by consensus using 3 different ordinal scales and categorized as good, intermediate, and poor. Multivariable modeling was used to assess the effect of collateral status and treatment type on clinical outcome by modified Rankin Scale (mRS 0-2, mRS 0-1, and the ordinal mRS).
RESULTS:
Of 185 patients, 126 randomized to endovascular therapy (87.6% recanalized, 41.3% 90-day mRS 0-2) and 59 to intravenous tissue-type plasminogen activator only (60.5% recanalized, 30.5% 90-day mRS 0-2). In multivariable modeling, collateral status was a significant predictor of all clinical outcomes (P<0.05). Maximal benefit with endovascular treatment across all clinical outcomes was seen in patients with intermediate collaterals, some benefit in patients with good collaterals, and none in patients with poor collaterals, although small sample size limited the power of the analysis to show a statistically significant interaction between collateral status and treatment type (P>0.05).
CONCLUSION:
Using data from a large randomized controlled trial (IMS III), we show that baseline computed tomographic angiography collaterals are a robust determinant of final clinical outcome and could be used to select patients for endovascular therapy.
CLINICAL TRIAL REGISTRATION:
URL: http://www.clinicaltrials.gov/ct2/show/. Unique identifier: 0020NCT00359424.
AuthorsBijoy K Menon, Emmad Qazi, Vivek Nambiar, Lydia D Foster, Sharon D Yeatts, David Liebeskind, Tudor G Jovin, Mayank Goyal, Michael D Hill, Thomas A Tomsick, Joseph P Broderick, Andrew M Demchuk,
JournalStroke; a journal of cerebral circulation (Stroke) Vol. 46 Issue 5 Pg. 1239-44 (May 2015) ISSN: 1524-4628 [Electronic] United States
PMID25791716 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2015 American Heart Association, Inc.
Chemical References
  • Fibrinolytic Agents
  • Tissue Plasminogen Activator
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Brain Ischemia (radiography, therapy)
  • Cerebral Angiography
  • Collateral Circulation
  • Endovascular Procedures
  • Female
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Image Processing, Computer-Assisted
  • Male
  • Middle Aged
  • Stroke (radiography, therapy)
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator (therapeutic use)
  • Tomography, X-Ray Computed
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: